SIG Group AG / Key word(s): Issue of Debt/Issue of Debt SIG successfully places €450 million Schuldschein following strong demand from investors 13.05.2024 / 07:00 CET/CEST MEDIA RELEASE 13 May 2024 SIG successfully places €450 million Schuldschein following strong demand from investors SIG today announces it has successfully completed a €450 million Schuldschein placement. The notes are structured in tranches with maturities of four, five and seven years with both fixed and variable interest rates at competitive levels. The high level of demand from a wide range of invest...
SIG Group AG / Schlagwort(e): Anleiheemission/Anleiheemission SIG platziert Schuldscheindarlehen in Höhe von EUR 450 Millionen bei starker Nachfrage von Investoren 13.05.2024 / 07:00 CET/CEST MEDIENMITTEILUNG 13. Mai 2024 SIG platziert Schuldscheindarlehen in Höhe von EUR 450 Millionen bei starker Nachfrage von Investoren SIG hat erfolgreich ein Schuldscheindarlehen in Höhe von EUR 450 Millionen platziert. Die Emission besteht aus drei Tranchen mit Laufzeiten von vier, fünf und sieben Jahren mit festen und variablen Zinssätzen auf einem attraktiven Niveau. Aufgrund der hoh...
A director at CTS Global Equity Group Inc sold 37,000,000 shares at 0.680PHP and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
A director at Cemex Holdings Philippines Inc sold 1,300,000 shares at 1.383PHP and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
EQS-News: ProCredit Holding AG / Schlagwort(e): Quartalsergebnis/Quartals-/Zwischenmitteilung ProCredit startet mit starkem Q1-Ergebnis gut ins neue Geschäftsjahr 13.05.2024 / 06:58 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. ProCredit startet mit starkem Q1-Ergebnis gut ins neue Geschäftsjahr Konzernergebnis von 33,5 Mio. EUR entspricht einer Eigenkapitalrendite von 13,4 % Kreditportfolio wächst um 3,0 % mit gutem Beitrag aus allen Segmenten Wachstum der Einlagen um 2,8 %; Privatkunden als Haupttreiber im Einklang mit der aktu...
EQS-News: Newron Pharmaceuticals S.p.A. / Schlagwort(e): Studienergebnisse Newron veröffentlicht überzeugende zusätzliche Daten, welche die Wirksamkeit von Evenamide in der Zulassungsstudie 008A bei Schizophrenie-Patienten mit geringer Therapieansprache belegen 13.05.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Newron veröffentlicht überzeugende zusätzliche Daten, welche die Wirksamkeit von Evenamide in der Zulassungsstudie 008A bei Schizophrenie-Patienten mit geringer Therapieansprache belegen Weitere Analysen der St...
EQS-News: ProCredit Holding AG / Key word(s): Quarter Results/Quarterly / Interim Statement ProCredit with strong Q1 result and good start into the year 13.05.2024 / 06:58 CET/CEST The issuer is solely responsible for the content of this announcement. ProCredit with strong Q1 result and good start into the year Result of EUR 33.5 million corresponds to a return on equity of 13.4% Loan portfolio grows by 3.0%, with good contribution from all segments Deposits grow by 2.8%; private clients as major driver in line with updated business strategy Net interest margin of 3...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients 13.05.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change ...
A director at Swedish Orphan Biovitrum AB sold after exercising options/sold 58,480 shares at 280.829SEK and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Corbion reports the progress of its € 20 million share buyback program 6 May – 10 May 2024 Corbion hereby reports the transaction details related to its € 20 million share buyback program announced on 26 April 2024. During the week of 6 May up to and including 10 May 2024 a total of 56,299 shares were repurchased at an average price of €21.3620 for a total amount of €1,202,658.73. To date, the total consideration for shares repurchased amounts to €1,999,484.52 representing 10.00% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the pr...
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine Results Intended to Support Filing for Potential Label Extension for Use in Adolescents Saint-Herblain (France), May 13, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day 29 post-vaccination, the most recent analysis of study VLA1553-321 evaluated the safety and immunogenicity six months (D...
Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty Paris, May 13, 2024. As the largest private contributor to the security and independence of France's health ecosystem, Sanofi today announces an investment of more than €1 billion to create new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) a...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRY...
Kitron ASA - Initiation of share buyback program (2024-05-13) Kitron ASA initiates a share buyback in connection with remuneration to the board members. Kitron ASA ("Kitron" or the "Company") has decided to initiate a share buyback program of up to 30,000 of its own shares for a total maximum amount of NOK 900,000. The buyback program may be carried out in the period from this announcement and until 16 May 2024. The share buyback program will be carried out in accordance with the EC Commission Delegated Regulation (EU) No. 2016/1052 of 8 March 2016 regarding exemptions from market manipul...
Air France-KLM a remboursé les 48 millions d'euros restants d'OCEANE à échéance 2026 Paris, le 13 mai 2024 Air France-KLM a remboursé les 48 millions d'euros restants d'OCEANE à échéance 2026 Air France-KLM annonce aujourd'hui avoir remboursé en numéraire environ 48 millions d'euros de valeur nominale des obligations convertibles dont l’échéance est le 25 mars 2026 (les " OCEANE 2026 ", ISIN FR0013410628), en utilisant l'option de remboursement anticipé de la compagnie (" Clean Up Call Option ", qui fait partie des termes et conditions des obligations). Ce montant résiduel de rembourseme...
Coop Pank AS results for April 2024 Coop Pank’s financial results in April 2024: In April, number of the bank's clients increased by 2,400 and number of active clients increased by 1,500. By the end of the month number of clients reached 191,800 and number of active clients reached 85,900. Over the year, customer base has grown by 22%.Volume of the bank's customer deposits increased by 45 million euros, reaching 1.74 billion euros by the end of month. Deposits of corporate customers increased by 33 million euros and deposits of private customers increased by 1 million euros. The volume ...
Coop Pank AS 2024. aasta aprilli tulemused Coop Panga 2024. aasta aprillikuu majandustulemused: Panga klientide arv kasvas aprillis 2400 võrra ja aktiivselt arveldavate klientide arv kasvas 1500 võrra. Kuu lõpuks ulatus klientide arv 191 800-ni ja aktiivselt arveldavate klientide arv 85 900-ni. Aastaga on kliendibaas kasvanud 22%.Panga klientide hoiuste maht kasvas aprillis 45 miljoni euro võrra ulatudes kuu lõpu seisuga 1,74 miljardi euroni. Äriklientide hoiused kasvasid 33 miljoni euro võrra ja eraklientide hoiused kasvasid 1 miljoni euro võrra. Rahvusvahelistelt platvormidelt kaasatu...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.